0001077183-26-000010
SEC filingNeoGenomics, Inc. reported a net loss of $108.0 million for fiscal year 2025, driven by a loss from operations of $115.9 million despite generating $727.3 million in revenue. The company's gross margin was $314.3 million, representing a 43.2% gross margin rate. Operating expenses totaled $430.2 million, including significant impairment charges of $27.8 million. Cash flow from operations was positive at $5.2 million, but the company used $12.3 million in investing activities and $200.3 million in financing activities, primarily for convertible debt repayment of $201.2 million. The net change in cash was negative $207.4 million, reducing cash and cash equivalents to $159.6 million at year-end. Total assets stood at $1.36 billion with stockholders' equity of $836.6 million.
NeoGenomics reported a challenging fiscal year 2025 with a net loss of $108.0 million on revenue of $727.3 million. The company's loss from operations was $115.9 million, reflecting significant operating expenses of $430.2 million that exceeded gross profit of $314.3 million. Key non-cash charges included impairment charges of $27.8 million, depreciation of $36.1 million, and amortization of intangibles of $31.8 million. Despite the net loss, the company generated positive operating cash flow of $5.2 million through effective working capital management, including a $6.2 million decrease in accounts receivable and $1.5 million decrease in inventories.
The company reported total revenue of $727.3 million for fiscal year 2025. No segment breakdown or geographic revenue mix was provided in the available data. The cost of revenue was $413.0 million, resulting in gross profit of $314.3 million. The document does not disclose specific revenue drivers, growth rates by product line, or customer concentration information that would allow for detailed revenue analysis beyond the aggregate figures presented in the financial statements.
The company achieved a gross margin of 43.2% ($314.3 million gross profit on $727.3 million revenue). Operating expenses totaled $430.2 million, consisting of general and administrative expenses of $273.3 million, research and development of $37.1 million, sales and marketing of $92.0 million, and impairment charges of $27.8 million. This resulted in an operating margin of -15.9%. The impairment charges of $27.8 million significantly impacted profitability, while stock-based compensation of $41.3 million represented another substantial non-cash expense affecting the operating loss.
Operating activities generated $5.2 million in cash despite the net loss, primarily due to non-cash adjustments totaling $144.4 million and positive working capital changes. Investing activities used $12.3 million, mainly for property and equipment purchases of $27.0 million and business acquisitions of $6.5 million, partially offset by proceeds from maturing marketable securities of $20.1 million. Financing activities used $200.3 million, primarily for convertible debt repayment of $201.2 million. The balance sheet shows total assets of $1.36 billion, including $159.6 million in cash, $159.2 million in accounts receivable, and $524.3 million in goodwill. Total liabilities were $523.3 million, with $341.9 million in convertible senior notes as the largest component.
The filing does not contain specific forward-looking guidance, management projections, or explicit strategic priorities for future periods. No quantitative or qualitative outlook information was provided regarding revenue growth expectations, margin improvement targets, capital expenditure plans, or debt management strategies. The document focuses on historical financial results without disclosing management's expectations for future performance, market conditions, or operational initiatives that would typically appear in the MD&A section of a 10-K filing.